Anesthetic nasal spray for use in dentistry.
St. Renatus, LLC, a privately held company based in Fort Collins, Colorado, has announced it received U.S. Food and Drug Administration (FDA) approval on June 29, 2016 for KOVANAZE[TM] (tetracaine HCl and oxymetazoline HCl) Nasal Spray. This is the first product that allows for dental anesthesia to be administered through a nasal spray without using a needle.
The product is intended for use in dentistry as a topical anesthetic, delivered in the nasal cavity to achieve pulpal (tooth nerve) anesthesia for the restorative treatment of teeth. Like traditional dental injections, this product delivers a local dental anesthetic, but without the needle. It is indicated for regional anesthesia when performing a restorative procedure on Teeth 4-13 and A-J in adults and children who weigh 40 kg or more.
According top UPenn News, the spray was deemed safe and effective in a Phase 3 clinical trial led by University of Pennsylvania School of Dental Medicine researchers. The results of the study were published in the April 2016 Journal of the American Dental Association.
Source: PR Newswire and News.UPenn.edu.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 1, 2016|
|Previous Article:||Genetic variations influence obesity effect in periodontal disease progression.|
|Next Article:||Are we HIPAA compliant when sending and storing patient records electronically?|